Skip to main content

Drug Interactions between Omega MonoPure DHA EC and Ongentys

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between Omega MonoPure DHA EC and Ongentys. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Omega MonoPure DHA EC

A total of 76 drugs are known to interact with Omega MonoPure DHA EC.

Ongentys

A total of 277 drugs are known to interact with Ongentys.

Drug and food interactions

Moderate

opicapone food

Applies to: Ongentys (opicapone)

ADJUST DOSING INTERVAL: Food may reduce the rate and extent of absorption of opicapone. When opicapone was administered following a moderate fat/moderate calorie meal, mean opicapone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 62% and 31%, respectively, while the time to reach peak concentration (Tmax) was delayed by 4 hours.

MANAGEMENT: Patients should avoid eating 1 to 2 hours before and after taking opicapone.

References (2)
  1. Cerner Multum, Inc. "Australian Product Information."
  2. (2020) "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer